Loading
ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters.
Open Targets scores its association with cancer at 0.61 (direct and indirect evidence; datatypes literature 0.98, animal model 0.27, genetic association 0.06, somatic mutation 0.78). IntOGen calls it a driver in 9 cohorts (4 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Cholangiocarcinoma, Colorectal Adenocarcinoma.
In plain words · ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
ELF3 (ETS-related transcription factor Elf-3) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Bladder & urothelial cancer, Colorectal cancer and Biliary tract cancer.
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT].
No product in this corpus aims at ELF3 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1997. Earliest sequence paper UniProt cites for the protein: Oettgen et al, Mol. Cell. Biol, 1997, "Isolation and characterization of a novel epithelium-specific transcription factor, ESE-1, a member of the ets family". Source.
Sources: HGNC HGNC:3318 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P78545 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000163435 (association with cancer (MONDO_0004992) 0.61; per-cancer scores at or above 0.5: urinary bladder cancer 0.56 (GraphQL API, CC0)); IntOGen ELF3 (driver in 9 cohorts (Act 4, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Transcriptional activator that binds and transactivates ETS sequences containing the consensus nucleotide core sequence GGA[AT]. Acts synergistically with POU2F3 to transactivate the SPRR2A promoter and with RUNX1 to transactivate the ANGPT1 promoter. Also transactivates collagenase, CCL20, CLND7, FLG, KRT8, NOS2, PTGS2, SPRR2B, TGFBR2 and TGM3 promoters. Represses KRT4 promoter activity. Involved in mediating vascular inflammation. May play an important role in epithelial cell differentiation and tumorigenesis. Location: Cytoplasm; Nucleus (UniProt). Locus 1q32.1 (HGNC).
| Cancer | Prevalence | Measure | Note | Source |
|---|---|---|---|---|
| Gallbladder cancer | 9% | Frameshift and truncating mutation | Mutation in 21 of 244 samples, 8.6%, in cBioPortal gbc_mskcc_2022; a significantly altered gene across 260 biliary cancers (Nakamura 2015) and across 167 gallbladder cancers, where most alterations were frameshifts yielding T-cell-activating neoantigens (Pandey 2020). | cBioPortal (TCGA) |
Approximate, population-level figures; the measure column says what was counted. Ranges show the midpoint as a bar.
A three-continent cohort from high-incidence countries, and the origin of the idea that a shared frameshift (ELF3) could be a vaccine target in a cancer with few targets. CTNNB1 and STK11 from this list recur in the MSK data.
The paper that separated the biliary tree into molecular subtypes: FGFR2 and IDH belong to the intrahepatic ducts, while gallbladder cancer carries HER2, ELF3 and an APOBEC signature. Its hypermutated, checkpoint-high poor-prognosis group foreshadowed immunotherapy.
Query for this target: (TITLE:"ELF3" OR ABSTRACT:"ELF3" OR TITLE:"E74 like ETS transcription factor 3" OR ABSTRACT:"E74 like ETS transcription factor 3" OR TITLE:"ETS-related transcription factor Elf-3" OR ABSTRACT:"ETS-related transcription factor Elf-3" OR TITLE:"EPR-1" OR ABSTRACT:"EPR-1" OR TITLE:"ESE-1" OR ABSTRACT:"ESE-1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ELF3, not a curated reading list.
Shares Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate, Bladder & urothelial cancer, IntOGen, Open Targets Platform.
Shares Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate, Gallbladder cancer, IntOGen, Open Targets Platform.
Shares Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate, Biliary tract cancer (cholangiocarcinoma), IntOGen, Open Targets Platform.
Shares Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate, IntOGen, Open Targets Platform, Colorectal cancer.
Shares Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate, Gallbladder cancer, IntOGen, Open Targets Platform.